米托蒽醌为主联合化疗治疗急性白血病的临床研究

Clinical study on treating acute leukemia with combinative chemotherapy based on mitoxantrone

目的 :观察米托蒽醌治疗初治、难治和复发急性白血病 35例的临床疗效和不良反应 ,并通过检测 1 70 P表达探讨米托蒽醌与 1 70 P的关系。方法 :急性非淋巴细胞白血病采用 MA方案 ,急性淋巴细胞白血病采用 VMP或 VML P方案 ;用免疫化学ABC技术检测化疗前后骨髓细胞 1 70 P表达。结果 :初治组 14例中 ,CR8例 ,PR3例 ,有效例 ,PR5例 ,有效率 5 1.14% ;1 70 P检测发现难治复发组中阳性率高于初治组 (P<0 .0 1) ,1 70 P表达阳性的 12例患者经化疗后有6例达 CR且 1 70 P表达转为阴性。结论 :米托蒽醌为主的联合化疗治疗初治、复发和难治急性白血病有较好的疗效 ,米托蒽醌对1 70

AIM: To investigate therapeutic efficiency and adverse drug reaction in treating initial, refractory, relapse cases of acute leukemia with mitoxantrone, along with exploring the relationship between mitoxantrone and P 170 through determinating the express of 170 P. METHODS: Adopting MA regimen to cure acute nonlymphocytic leukemia, VMP, VMLP regimen to acute lymphocytic leukemia; the express of 170 P on bone marrow cell were determined by immunochemistry ABC technology before and after therapy. RESULTS: Among 14 initial cases, 8 were complete remission, 3 were partly remission, the efficiency rate was 78 56%. Among 21 refractory and relapse cases, 7 were complete remission, 15 were partly remission, the efficiency rate was 51 14%. The study revealed the higher positive rate of 170 P in refractory and relapse cases than that in initial cases ( P <0 01). Six cases of 12 patients with 170 P got complete remission after therapy and their express of 170 P became negative. CONCLUSION: The combinative chemotherapy based on mitoxantrone has been proved efficiency in treating initial refractory and relapse cases of acute leukemia. Mitoxantrone is also effective for the treatment of refractory and relapse cases with the express of P 170 .